Lonza

© GettyImages/Ca-ssis

Lonza: Robust industry fundamentals are supportive of growth

By Jane Byrne

Despite an uncertain macroeconomic environment, Lonza says its ‘resilient’ business model and sustained market demand delivered a strong financial performance in 2022, in line with the Swizterland based CDMO’s outlook.

© GettyImages/Yuuji

Lonza expands team, labs for cell and gene development

By Jane Byrne

Lonza is to increase the size of the cell and gene therapy (CGT) development space at its Houston facility; the expansion will include viral vector-based process development and analytical development laboratories.

© GettyImages/Monty Rakusen

Lonza and Doer Biologics in expression system license deal

By Jane Byrne

Lonza has signed a licensing agreement with clinical-stage biopharma, Zhejiang Doer Biologics, whereby the Hangzhou, China based biopharma company will develop multi-specific biotherapeutics using the Swiss CDMO’s XS Pichia.

Five biggest CDMO deals of the year

Five deals reshaping the CDMO industry this year

By Ben Hargreaves

The major trend so far in 2019 is the willingness to deploy capital to expand services in the cell and gene therapy sector, and we outline the five most significant deals thus far.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers